文献速递前列腺癌

用于前列腺癌主动监测风险分层的减法归一化免疫细胞分析特征模型的开发与优化

Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
PubMed 文献 · J Urol · 2023-12-26

研究开发并验证了一种基于血液的免疫细胞转录组特征模型,用于识别主动监测(AS)中隐藏的高危前列腺癌患者。模型在训练队列(n=1017)和验证队列(n=1198)中建立,结合2种免疫细胞转录组特征、PSA密度和年龄,AUC为0.73(95%CI:0.69-0.77),显著优于PSA密度(AUC 0.69,95%CI:0.65-0.73;P<.001)。模型阴性预测值90%,阳性预测值50%。

要点

  • 免疫细胞转录组模型结合PSA密度和年龄,AUC为0.73(95%CI:0.69-0.77)。
  • 模型显著优于PSA密度(P<.001),后者AUC为0.69(95%CI:0.65-0.73)。
  • 模型阴性预测值90%,阳性预测值50%。

核心结论

  • 免疫细胞转录组模型在进一步于预期用途队列中验证前,可能为考虑主动监测的个体患者提供风险分层的有前景工具。

研究设计与样本

  • 研究纳入经医生评估需要前列腺活检的男性,训练队列n=1017,验证队列n=1198,均在活检时采集血样。
  • 从外周血单个核细胞中纯化CD2+和CD14+免疫细胞,提取RNA并测序。
  • 在训练队列上基于美国国家综合癌症网络(NCCN)前列腺癌指南构建正则化回归模型预测侵袭性,并在仅活检阳性的独立队列中验证,以NCCN不利中间风险及以上作为侵袭性结局。

主要发现

  • 用于主动监测场景的最佳最终模型结合了基于2种细胞类型的免疫细胞转录组特征、PSA密度和年龄,AUC为0.73(95%CI:0.69-0.77)。
  • 模型显著优于PSA密度作为生物标志物(P<.001),PSA密度的AUC为0.69(95%CI:0.65-0.73)。
  • 模型产生个体化患者风险评分,阴性预测值为90%,阳性预测值为50%。

关键数值与推荐

  • 模型AUC为0.73(95%CI:0.69-0.77),PSA密度AUC为0.69(95%CI:0.65-0.73),两者比较P<.001。
  • 模型阴性预测值90%,阳性预测值50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要在预期用途队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Less invasive decision support tools are desperately needed to identify occult high-risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of reasons, many men on AS with low- or intermediate-risk disease forgo the necessary repeat surveillance biopsies needed to identify potentially higher-risk PCa. Here, we describe the development of a blood-based immunocyte transcriptomic signature to identify men harboring occult aggressive PCa. We then validate it on a biopsy-positive population with the goal of identifying men who should not be on AS and confirm those men with indolent disease who can safely remain on AS. This model uses subtraction-normalized immunocyte transcriptomic profiles to risk-stratify men with PCa who could be candidates for AS. MATERIALS AND METHODS: Men were eligible for enrollment in the study if they were determined by their physician to have a risk profile that warranted prostate biopsy. Both training (n = 1017) and validation cohort (n = 1198) populations had blood samples drawn coincident to their prostate biopsy. Purified CD2+ and CD14+ immune cells were obtained from peripheral blood mononuclear cells, and RNA was extracted and sequenced. To avoid overfitting and unnecessary complexity, a regularized regression model was built on the training cohort to predict PCa aggressiveness based on the National Comprehensive Cancer Network PCa guidelines. This model was then validated on an independent cohort of biopsy-positive men only, using National Comprehensive Cancer Network unfavorable intermediate risk and worse as an aggressiveness outcome, identifying patients who were not appropriate for AS. RESULTS: The best final model for the AS setting was obtained by combining an immunocyte transcriptomic profile based on 2 cell types with PSA density and age, reaching an AUC of 0.73 (95% CI: 0.69-0.77). The model significantly outperforms (P < .001) PSA density as a biomarker, which has an AUC of 0.69 (95% CI: 0.65-0.73). This model yields an individualized patient risk score with 90% negative predictive value and 50% positive predictive value. CONCLUSIONS: While further validation in an intended-use cohort is needed, the immunocyte transcriptomic model offers a promising tool for risk stratification of individual patients who are being considered for AS.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Van Neste L, Henao R, Wojno KJ, et al. Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification. J Urol. 2023. PMID: 38147400. doi:10.1097/JU.0000000000003824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。